Cost-effectiveness of extended cessation treatment for older smokers

Addiction

Volumn 109, Issue 2, 2014, Pages 314-322

  Barnett, Paul G ^a,b   Wong, Wynnie ^a   Jeffers, Abra ^b   Munoz, Ricardo ^a,c   Humfleet, Gary ^a   Hall, Sharon ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b STANFORD UNIVERSITY   (United States)

^c PALO ALTO UNIVERSITY   (United States)

Author keywords

Clinical trial; Cognitive behaviorial treatment; Cost effectiveness analysis; Extended smoking cessation; Incremental cost effectiveness ratio; Markov model; Tobacco use cessation

Indexed keywords

NICOTINE GUM;

AGED; COGNITIVE THERAPY; COMPARATIVE STUDY; CONTROLLED STUDY; COST BENEFIT ANALYSIS; COUNSELING; ECONOMICS; FEMALE; HUMAN; MALE; MIDDLE AGED; PATIENT ATTITUDE; PROCEDURES; QUALITY ADJUSTED LIFE YEAR; RANDOMIZED CONTROLLED TRIAL; SECONDARY PREVENTION; SMOKING CESSATION; STATISTICS AND NUMERICAL DATA; TOBACCO USE DISORDER; TREATMENT OUTCOME; VERY ELDERLY;

AGED; AGED, 80 AND OVER; COGNITIVE THERAPY; COST-BENEFIT ANALYSIS; COUNSELING; FEMALE; HUMANS; MALE; MIDDLE AGED; PATIENT ACCEPTANCE OF HEALTH CARE; QUALITY-ADJUSTED LIFE YEARS; SECONDARY PREVENTION; SMOKING CESSATION; TOBACCO USE CESSATION PRODUCTS; TOBACCO USE DISORDER; TREATMENT OUTCOME;

EID: 84892429203     PISSN: 09652140     EISSN: 13600443     Source Type: Journal    
DOI: 10.1111/add.12404     Document Type: Article

References (43)

1. Cummings S. R., Rubin S. M., Oster G. The cost-effectiveness of counseling smokers to quit. JAMA 1989; 261: 75-79.
2. Cromwell J., Bartosch W. J., Fiore M. C., Hasselblad V., Baker T. Cost-effectiveness of the clinical practice recommendations in the AHCPR guideline for smoking cessation. Agency for Health Care Policy and Research. JAMA 1997; 278: 1759-1766.
3. Fiscella K., Franks P. Cost-effectiveness of the transdermal nicotine patch as an adjunct to physicians' smoking cessation counseling. JAMA 1996; 275: 1247-1251.
4. Song F., Raftery J., Aveyard P., Hyde C., Barton P., Woolacott N. Cost-effectiveness of pharmacological interventions for smoking cessation: a literature review and a decision analytic analysis. Med Decis Making 2002; 22: S26-37.
5. Coleman T., Agboola S., Leonardi-Bee J., Taylor M., McEwen A., McNeill A. Relapse prevention in UK Stop Smoking Services: current practice, systematic reviews of effectiveness and cost-effectiveness analysis. Health Technol Assess 2010; 14: 1-152, iii-iv.
6. Ronckers E. T., Groot W., Ament A. J. Systematic review of economic evaluations of smoking cessation: standardizing the cost-effectiveness. Med Decis Making 2005; 25: 437-448.
7. Woolacott N. F., Jones L., Forbes C. A., Mather L. C., Sowden A. J., Song F. J. etal. The clinical effectiveness and cost-effectiveness of bupropion and nicotine replacement therapy for smoking cessation: a systematic review and economic evaluation. Health Technol Assess 2002; 6: 1-245.
8. Hajek P., Stead L. F., West R., Jarvis M., Lancaster T. Relapse prevention interventions for smoking cessation. Cochrane Database Syst Rev 2009; 1: CD003999.
9. Lancaster T., Hajek P., Stead L. F., West R., Jarvis M. J. Prevention of relapse after quitting smoking: a systematic review of trials. Arch Intern Med 2006; 166: 828-835.
10. Agboola S., McNeill A., Coleman T., Leonardi Bee J. A systematic review of the effectiveness of smoking relapse prevention interventions for abstinent smokers. Addiction 2010; 105: 1362-1380.
11. Chirikos T. N., Herzog T. A., Meade C. D., Webb M. S., Brandon T. H. Cost-effectiveness analysis of a complementary health intervention: the case of smoking relapse prevention. Int J Technol Assess Health Care 2004; 20: 475-480.
12. Taylor M., Leonardi-Bee J., Agboola S., McNeill A., Coleman T. Cost effectiveness of interventions to reduce relapse to smoking following smoking cessation. Addiction 2011; 106: 1819-1826.
13. Hall S. M., Humfleet G. L., Munoz R. F., Reus V. I., Robbins J. A., Prochaska J. J. Extended treatment of older cigarette smokers. Addiction 2009; 104: 1043-1052.
14. Rimer B. K., Orleans C. T., Keintz M. K., Cristinzio S., Fleisher L. The older smoker. Status, challenges and opportunities for intervention. Chest 1990; 97: 547-553.
15. Orleans C. T. Reducing tobacco harms among older adults: a critical agenda for tobacco control. Tob Control 1997; 6: 161-163.
16. Montgomery A. A., Peters T. J., Little P. Design, analysis and presentation of factorial randomised controlled trials. BMC Med Res Methodol 2003; 3: 26.
17. Manning W. G., Mullahy J. Estimating log models: to transform or not to transform? J Health Econ 2001; 20: 461-494.
18. Levy D. T., Graham A. L., Mabry P. L., Abrams D. B., Orleans C. T. Modeling the impact of smoking-cessation treatment policies on quit rates. Am J Prev Med 2010; 38: S364-372.
19. Hawkins J., Hollingworth W., Campbell R. Long-term smoking relapse: a study using the British Household Panel Survey. Nicotine Tob Res 2010; 12: 1228-1235.
20. Gilpin E. A., Pierce J. P., Farkas A. J. Duration of smoking abstinence and success in quitting. J Natl Cancer Inst 1997; 89: 572-576.
21. Wetter D. W., Cofta-Gunn L., Fouladi R. T., Cinciripini, P. M., Sui, D., Gritz, E. R. Late relapse/sustained abstinence among former smokers: a longitudinal study. Prev Med 2004; 39: 1156-1163.
22. Krall E. A., Garvey A. J., Garcia R. I. Smoking relapse after 2 years of abstinence: findings from the VA Normative Aging Study. Nicotine Tob Res 2002; 4: 95-100.
23. Woloshin S., Schwartz L. M., Welch H. G. The risk of death by age, sex, and smoking status in the United States: putting health risks in context. J Natl Cancer Inst 2008; 100: 845-853.
24. Woloshin S., Schwartz L. M., Welch H. G. Risk charts: putting cancer in context. J Natl Cancer Inst 2002; 94: 799-804.
25. Prescott E., Osler M., Andersen P. K., Hein H. O., Borch-Johnsen K., Lange P. etal. Mortality in women and men in relation to smoking. Int J Epidemiol 1998; 27: 27-32.
26. Friedman G. D., Tekawa I., Salder M., Sidney S. Smoking and mortality: the Kaiser Permanente experience. Changes in cigarette-related disease risks and their implications for prevention and control. Monogr Natl Cancer Inst 1997; 97: 472-499.
27. Kenfield S. A., Stampfer M. J., Rosner B. A., Colditz G. A. Smoking and smoking cessation in relation to mortality in women. JAMA 2008; 299: 2037-2047.
28. LaCroix A. Z., Lang J., Scherr P., Wallace R. B., Cornoni-Huntley J., Berkman L. etal. Smoking and mortality among older men and women in three communities. N Engl J Med 1991; 324: 1619-1625.
29. Kawachi I., Colditz G. A., Stampfer M. J., Willett W. C., Manson J. E., Rosner B. etal. Smoking cessation in relation to total mortality rates in women. A prospective cohort study. Ann Intern Med 1993; 119: 992-1000.
30. Streppel M. T., Boshuizen H. C., Ocke M. C., Kok F. J., Kromhout D. Mortality and life expectancy in relation to long-term cigarette, cigar and pipe smoking: the Zutphen Study. Tob Control 2007; 16: 107-113.
31. Bjartveit K., Tverdal A. Health consequences of sustained smoking cessation. Tob Control 2009; 18: 197-205.
32. Taylor D. H. Jr, Hasselblad V., Henley S. J., Thun M. J., Sloan F. A. Benefits of smoking cessation for longevity. Am J Public Health 2002; 92: 990-996.
33. van Baal P. H., Hoogenveen R. T., de Wit G. A., Boshuizen H. C. Estimating health-adjusted life expectancy conditional on risk factors: results for smoking and obesity. Popul Health Metr 2006; 4: 14.
34. Sloan F. A. The Price of Smoking. Cambridge, MA: MIT Press; 2004.
35. Bronnum-Hansen H., Juel K. Estimating mortality due to cigarette smoking: two methods, same result. Epidemiology 2000; 11: 422-426.
36. Howard P., Knight C., Boler A., Baker C. Cost-utility analysis of varenicline versus existing smoking cessation strategies using the BENESCO simulation model: application to a population of US adult smokers. Pharmacoeconomics 2008; 26: 497-511.
37. Javitz H. S., Swan G. E., Zbikowski S. M., Curry S. J., McAfee T. A., Decker D. L. etal. Cost-effectiveness of different combinations of bupropion SR dose and behavioral treatment for smoking cessation: a societal perspective. Am J Manag Care 2004; 10: 217-226.
38. Godfrey C., Parrott S., Coleman T., Pound E. The cost-effectiveness of the English smoking treatment services: evidence from practice. Addiction 2005; 100: 70-83.
39. Vogl M., Wenig C. M., Leidl R., Pokhrel S. Smoking and health-related quality of life in English general population: implications for economic evaluations. BMC Public Health 2012; 12: 203.
40. van Hout B. A., Al M. J., Gordon G. S., Rutten F. F. Costs, effects and C/E-ratios alongside a clinical trial. Health Econ 1994; 3: 309-319.
41. Stapleton J. A., West R. A direct method and ICER tables for the estimation of the cost-effectiveness of smoking cessation interventions in general populations: application to a new cytisine trial and other examples. Nicotine Tob Res 2012; 14: 463-471.
42. Warner K. E. Cost effectiveness of smoking-cessation therapies. Interpretation of the evidence-and implications for coverage. Pharmacoeconomics 1997; 11: 538-549.
43. Hyland A., Li Q., Bauer J. E., Giovino G. A., Steger C., Cummings K. M. Predictors of cessation in a cohort of current and former smokers followed over 13 years. Nicotine Tob Res 2004; 6: S363-369.